海角破解版

CHIR99021

WNT pathway activator; Inhibits GSK3

CHIR99021

WNT pathway activator; Inhibits GSK3

Catalog #
(Select a product)
WNT pathway activator; Inhibits GSK3
Request Pricing Request Pricing

Overview

CHIR99021 is an aminopyrimidine derivative that is an extremely potent glycogen synthase kinase (GSK) 3 inhibitor, inhibiting both GSK3尾 (IC鈧呪個 = 6.7 nM) and GSK3伪 (IC鈧呪個 = 10 nM) (Ring et al.). GSK3 is a serine/threonine kinase that is a key inhibitor of the WNT pathway; therefore CHIR99021 functions as a WNT activator. It shows little activity against a large panel of kinases including CDK2 and other serine/threonine kinases such as MAPK and PKB (Bain et al.).

MAINTENANCE AND SELF-RENEWAL
路 Maintains undifferentiated mouse ES cells in combination with PD0325901, in the absence of LIF (Ying et al.).
鈭 Promotes self-renewal of human ES cells and mouse epiblast stem cells in combination with IWR-1 (Kim et al.).
鈭 Allows derivation of ES cells from refractory mouse strains (Kiyonari et al., Ying et al.) and rat (Li P et al.) in combination with other small molecules.
路 Maintains human and mouse hematopoietic stem cells in cytokine-free conditions, in combination with rapamycin (Huang et al.).
路 Promotes growth of mouse and human intestinal stem cells (Wang et al.).

REPROGRAMMING
路 Enables chemical reprogramming (without genetic factors) of mouse embryonic fibroblasts to iPS cells, in combination with Forskolin, Tranylcypromine, Valproic Acid, 3-Deazaneplanocin A, and E-616452 (Hou et al.).
鈭 Promotes reprogramming of human somatic cells to iPS cells using OCT4, in combination with other small molecules (Zhu et al.).
鈭 With OCT4, transdifferentiates human CD34+ hematopoietic cells to mesenchymal stem cells (Meng et al.).
路 Direct lineage reprogramming of fibroblasts to mature neurons, in combination with Valproic Acid, RepSox, Forskolin, SP600125, G枚6983 and Y-27632 (Hu et al.).
路 Direct lineage reprogramming of fibroblasts to mature neurons, in combination with Forskolin, ISX-9, SB431542, and I-BET151 (Li et al.).
路 Generates mouse-like or 鈥済round state鈥 iPS cells from human and rat somatic cells, in combination with PD0325901 and A 83-01 (Li W et al. 2009).

DIFFERENTIATION
路 Promotes differentiation of insulin-producing cells from human iPS cells (Kunisada et al.).
鈭 Promotes differentiation of cardiomyocytes from human ES and iPS cells (Lian et al.).
鈭 Generates and maintains primitive neural stem cells from human ES cells, in combination with SB431542 and Human Recombinant LIF (Li W et al. 2011).
Alternative Names
CT 99021
Cell Type
Cardiomyocytes, PSC-Derived, Endoderm, PSC-Derived, Hematopoietic Stem and Progenitor Cells, Mesoderm, PSC-Derived, Neural Cells, PSC-Derived, Neurons, Pancreatic Cells, Pluripotent Stem Cells
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Differentiation, Expansion, Maintenance, Reprogramming
Area of Interest
Neuroscience, Stem Cell Biology
CAS Number
252917-06-9
Chemical Formula
颁鈧傗倐贬鈧佲倛颁濒鈧侼鈧
Molecular Weight
465.3 g/mol
Purity
鈮 95%
Pathway
WNT
Target
GSK3

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
100-1042, 72054, 72052
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-1042
Lot #
All
Language
English
Document Type
Product Name
Catalog #
72054, 72052
Lot #
All
Language
English

Resources and Publications

Publications (80)

Generation of Functional Patient-Specific Thymus Organoids From Human Pluripotent Stem Cells (hPSCs) Using Air鈥揕iquid Interface Culture S. A. Ramos, H. A. Russ Bio-protocol 2026 May

Abstract

The thymus is critical for the establishment of a functional and self-tolerant adaptive immune system, but it involutes with age, resulting in reduced naive T-cell output. Generation of a functional human thymus from human pluripotent stem cells (hPSCs) is an attractive regenerative medicine strategy. Direct differentiation of thymic epithelial progenitors (TEPs) from hPSCs has been demonstrated in vitro, but functional thymic epithelial cells (TECs) develop only after transplantation of TEPs in vivo. Functional human reaggregated thymic organoid cultures (RTOCs) and artificial thymic organoids (ATOs) cultured at the air鈥搇iquid interface support T-cell development in vitro and in vivo and permit the interrogation of human thymic function and T-cell development. However, these approaches require access to primary human tissues or murine bone marrow stromal cells, are allogeneic, and do not support negative selection. Recently, we reported the directed differentiation of induced PSCs (iPSCs) to functional thymic epithelial progenitors (TEPs) that support murine T-cell development after transplantation in nude mice. Here, we combined hPSC-derived TEPs, hematopoietic progenitor cells (HPCs), and mesenchymal cells, differentiated from the same hPSC line, and generated functional isogenic stem cell鈥揹erived thymic organoids (sTOs). Our revised protocol improves our TEP differentiation process and allows the generation of functional isogenic, patient-specific thymic organoids in vitro.
Modeling neurovascular dysfunction in Alzheimer鈥檚 disease using an isogenic brain-chip model A. N. Shen et al. Fluids and Barriers of the CNS 2026 Jan

Abstract

Background: The pathology of Alzheimer鈥檚 Disease (AD) is characterized by aggregates of amyloid beta (A尾) peptides and neurofibrillary tau tangles. Increased blood-brain barrier (BBB) permeability and reduced A尾 clearance, which signal neurovascular dysfunction, have also been proposed as early markers of AD. Despite intense scrutiny, the mechanisms of AD remain elusive and novel treatments that address core symptoms of dementia are limited. New alternative methods (NAMs) aim to develop in-vitro translational models that recapitulate human pathology more accurately than previous models and could contribute to the development of new therapies. Methods: Here, we developed a NAM model of the cortical neurovascular unit (NVU) using brain cells derived from human induced pluripotent stem cells (hiPSCs) from a patient with AD and a healthy individual. Differentiated neurons, astrocytes, pericytes, microglia, and brain-like microvascular endothelial cells were cultured in a microphysiological system to create a brain-chip model to evaluate NVU-related endpoints. Results: Compared to control, AD brain-chips had reduced claudin-5 and ZO-1 expression and increased paracellular permeability. AD brain-chips also had decreased activity of the efflux transporter P-glycoprotein (P-gp), but its expression was unchanged. In AD brain-chips, levels of A尾42, total tau, and p-tau 181 were decreased in protein lysates from the brain channel, while levels of total tau and p-tau 181 were increased in protein lysates from the vascular channel. Finally, AD brain-chips had increased levels of the proinflammatory markers IL-6 and MCP-1 in effluent from both brain and vascular channels. Conclusion: In this brain-chip model, we showed A尾-independent NVU dysfunction that was related to neuroinflammation and vascular tau accumulation. This study demonstrates the utility of the brain-chip model to evaluate changes in NVU functions induced by AD-like pathology and highlights donor-specific responses associated with the use of hiPSC-derived models.
Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis X. Hua et al. Theranostics 2026 Jan

Abstract

Background: Chronic myocarditis (CMYO) progresses to fibrosis and heart failure, yet no therapies effectively target fibrosis. Fibroblast activation protein (FAP) marks pathogenic myofibroblasts, but its therapeutic potential remains unexplored in inflammatory settings.Methods: Using bulk/scRNA-seq of human myocarditis samples, we identified FAP as a fibrosis-specific marker. We engineered FAP-targeted CAR-T (FAP.CAR-T) cells and tested their efficacy in autoimmune (EAM) and viral (CVB3) myocarditis models. Human cardiac organoids (hCOs) treated with IL-17A modeled inflammatory fibrosis.Results: FAP expression correlated with fibrosis severity in patients (r = 0.96, P = 0.0028). In EAM and CVB3 models, FAP.CAR-T cells reduced fibrosis by 65% and 55%, respectively (P < 0.001), restored ejection fraction to higher than 65%. hCOs treated with FAP.CAR-T cells showed 55% less fibrosis (P < 0.05). No toxicity was observed in healthy mice.Conclusions: FAP.CAR-T cells eliminate fibrosis-driving myofibroblasts, reversing cardiac dysfunction in chronic myocarditis. This strategy, validated in human organoids, offers translatable immunotherapy for fibrosis-driven heart disease.